Top-Rated StocksTop-RatedNASDAQ:PALI Palisade Bio (PALI) Stock Price, News & Analysis $2.14 -0.01 (-0.47%) Closing price 04:00 PM EasternExtended Trading$2.11 -0.03 (-1.40%) As of 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Palisade Bio Stock (NASDAQ:PALI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Palisade Bio alerts:Sign Up Key Stats Today's Range$2.06▼$2.1550-Day Range$1.68▼$2.2452-Week Range$0.53▼$2.86Volume1.60 million shsAverage Volume3.80 million shsMarket Capitalization$372.94 millionP/E RatioN/ADividend YieldN/APrice Target$9.00Consensus RatingBuy Company Overview Palisade Bio, Inc. is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity. The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors. Palisade Bio is also advancing a pipeline of next‐generation candidates designed to support combination approaches with checkpoint inhibitors, adoptive cell therapies and other standard‐of‐care modalities. The platform’s modular design enables the development of both injectable and implantable formats to address a variety of tumor types and anatomic locations. Palisade Bio operates out of facilities in the United States and collaborates with academic research centers, contract research organizations and biotechnology partners to accelerate its clinical programs. The company maintains a management team with extensive experience in oncology drug development, immunology and precision medicine. As it progresses through clinical milestones, Palisade Bio aims to validate its platform’s capacity to enhance anti‐tumor efficacy while reducing systemic immune‐related adverse events. AI Generated. May Contain Errors. Read More Palisade Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScorePALI MarketRank™: Palisade Bio scored higher than 63% of companies evaluated by MarketBeat, and ranked 249th out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingBuy Consensus RatingPalisade Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 7 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialPalisade Bio has a consensus price target of $9.00, representing about 320.6% upside from its current price of $2.14.Amount of Analyst CoveragePalisade Bio has only been the subject of 4 research reports in the past 90 days.Read more about Palisade Bio's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Palisade Bio are expected to decrease in the coming year, from ($0.22) to ($0.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Palisade Bio is -2.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Palisade Bio is -2.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPalisade Bio has a P/B Ratio of 2.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.43% of the float of Palisade Bio has been sold short.Short Interest Ratio / Days to CoverPalisade Bio has a short interest ratio ("days to cover") of 14.58, which indicates bearish sentiment.Change versus previous monthShort interest in Palisade Bio has recently decreased by 8.98%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPalisade Bio does not currently pay a dividend.Dividend GrowthPalisade Bio does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment0.48 News SentimentPalisade Bio has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Palisade Bio this week, compared to 4 articles on an average week.Search Interest11 people have searched for PALI on MarketBeat in the last 30 days. This is an increase of 10% compared to the previous 30 days.MarketBeat Follows6 people have added Palisade Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Palisade Bio insiders have sold 64.02% more of their company's stock than they have bought. Specifically, they have bought $250,100.00 in company stock and sold $410,226.00 in company stock.Percentage Held by Insiders0.07% of the stock of Palisade Bio is held by insiders.Percentage Held by Institutions11.79% of the stock of Palisade Bio is held by institutions.Read more about Palisade Bio's insider trading history. Receive PALI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Palisade Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PALI Stock News HeadlinesPalisade Bio, Inc.: Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 DevelopmentAugust 11 at 11:58 PM | finanznachrichten.deAnalysts’ Top Healthcare Picks: Palisade Bio (PALI), Sarepta Therapeutics (SRPT)August 11 at 11:58 PM | theglobeandmail.comOne wafer-scale chip does in minutes what AI takes daysNVIDIA has dominated the AI computing race, but history shows even titans can be dethroned, just ask IBM. Three companies are converging in what one publisher calls the Trillion Dollar Triangle, a partnership that could make today's data centers obsolete. A new video breaks down the full story, including the names behind this potential shift in computing power.August 14 at 1:00 AM | Eagle Publishing (Ad)Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 DevelopmentAugust 10, 2026 | finance.yahoo.comPalisade Bio Reports Q2 2026 Results, Advances PALI-2108 Into Phase 2 Development for Ulcerative Colitis and Crohn’s DiseaseAugust 10, 2026 | quiverquant.comQPalisade Bio (PALI) to Release Quarterly Earnings on MondayAugust 9, 2026 | americanbankingnews.comPalisade Bio jumps following Oppenheimer outperform initiationJuly 23, 2026 | msn.comPalisade Bio to Participate in the Leerink Partners Therapeutics ForumJuly 10, 2026 | markets.businessinsider.comSee More Headlines PALI Stock Analysis - Frequently Asked Questions How have PALI shares performed this year? Palisade Bio's stock was trading at $2.35 on January 1st, 2026. Since then, PALI stock has decreased by 8.9% and is now trading at $2.14. How were Palisade Bio's earnings last quarter? Palisade Bio, Inc. (NASDAQ:PALI) announced its earnings results on Monday, August, 10th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.05) by $0.00. The firm had revenue of $0.50 million for the quarter, compared to analysts' expectations of $0.50 million. When did Palisade Bio's stock split? Palisade Bio shares reverse split before market open on Monday, April 8th 2024.The 1-15 reverse split was announced on Monday, April 8th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are Palisade Bio's major shareholders? Palisade Bio's top institutional investors include BlackRock Inc. (6.01%), Landscape Capital Management L.L.C. (0.25%), Bank of New York Mellon Corp (0.20%) and Deutsche Bank AG (0.08%). Insiders that own company stock include Robert Jr Baltera, John David Finley, Mitchell Lawrence Jones, Donald Allen Williams and Robert J Trenschel. View institutional ownership trends. How do I buy shares of Palisade Bio? Shares of PALI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Palisade Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Palisade Bio investors own include Iterum Therapeutics (ITRM), Oncobiologics (OTLK), Bionano Genomics (BNGO), PayPal (PYPL) and Tesla (TSLA). Company Calendar Last Earnings8/10/2026Today8/14/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (10m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 PALI's financial health is in the Green zone, according to TradeSmith. PALI has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:PALI CIK1357459 Webwww.palisadebio.com Phone(858) 704-4900FaxN/AEmployees10Year Founded2005Price Target and Rating Average Price Target for Palisade Bio$9.00 High Price Target$25.00 Low Price Target$2.00 Potential Upside/Downside+321.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($1.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$16.78 million Net MarginsN/A Pretax MarginN/A Return on Equity-36.86% Return on Assets-34.89% Debt Debt-to-Equity RatioN/A Current Ratio23.71 Quick Ratio23.71 Sales & Book Value Annual Sales$250 thousand Price / Sales1,488.27 Cash FlowN/A Price / Cash FlowN/A Book Value$0.87 per share Price / Book2.45Miscellaneous Outstanding Shares174,270,000Free Float174,149,000Market Cap$372.07 million OptionableNot Optionable Beta1.52 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:PALI) was last updated on 8/14/2026 by MarketBeat.com Staff. From Our PartnersOne wafer-scale chip does in minutes what AI takes daysNVIDIA has dominated the AI computing race, but history shows even titans can be dethroned, just ask IBM. T...Eagle Publishing | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredWall Street is staring at the wrong AI tradeAnthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...The Oxford Club | SponsoredTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...Porter & Company | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredWhy November 27 Is Quickly Becoming America's Most Important Financial Date in DecadesAn estimated $10 trillion could move through a little known government initiative, according to analyst Joel L...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palisade Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Palisade Bio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
